Yahoo
NYSE American - Nasdaq Real Time Price USD

Calidi Biotherapeutics, Inc. (CLDI)

0.7001 +0.0211 (+3.11%)
At close: November 6 at 3:19:24 PM EST
0.7690 +0.0890 (+13.09%)
Pre-Market: 5:57:43 AM EST
Chart Range Bar
Loading chart for CLDI
  • Previous Close 0.6790
  • Open 0.6901
  • Bid --
  • Ask 0.7690 x 10000
  • Day's Range 0.6790 - 0.7099
  • 52 Week Range 0.6200 - 24.9600
  • Volume 15,720
  • Avg. Volume 119,284
  • Market Cap (intraday) 2.574M
  • Beta (5Y Monthly) 1.37
  • PE Ratio (TTM) --
  • EPS (TTM) -36.4700
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

www.calidibio.com

29

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CLDI
96.26%
S&P 500 (^GSPC)
7.76%

1-Year Return

CLDI
97.36%
S&P 500 (^GSPC)
9.77%

3-Year Return

CLDI
99.98%
S&P 500 (^GSPC)
68.96%

5-Year Return

CLDI
100.00%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY25
Revenue --
Earnings -5.15M
Profit Margin 0.00%

Q4

FY24

Q1

FY25

Q2

FY25

Q3

FY25

-4M
-2M
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -134.79%

  • Return on Equity (ttm)

    -672.22%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -23.45M

  • Diluted EPS (ttm)

    -36.4700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.07M

  • Total Debt/Equity (mrq)

    61.98%

  • Levered Free Cash Flow (ttm)

    -10.02M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: